Bliss Gvs Pharma Limited reported unaudited standalone earnings results for the third quarter and nine months ended Dec. 31, 2012. For the quarter, the company's net sales were INR 813.168 million compared to INR 629.606 million last year. Profit from operations before other income and finance cost and exceptional items was INR 236.228 million compared to INR 109.885 million last year. Basic and diluted EPS was INR 0.91, compared to INR 0.86 for the last year. For the nine months, the company's net sales were INR 2,479.811 million compared to INR 1,937.101 million last year. Profit from operations before other income and finance cost and exceptional items was INR 800.640 million compared to INR 519.348 million last year. Basic and diluted EPS was INR 4.94, compared to INR 4.38 for the last year.

Bliss GVS Pharma Ltd. announced that the Board of Directors of the company at its meeting held on February 13, 2013, has declared an interim dividend of 30% that is INR 0.30 per equity share for the year 2012-2013.

Bliss Gvs Pharma Limited announced that they will report Q3, 2013 results on Feb 13, 2013